Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Aug 29;8(8):CD004773.
doi: 10.1002/14651858.CD004773.pub3.

Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people

Ajibola A Awotiwon #  1 , Samuel Johnson #, George W Rutherford, Graeme Meintjes, Ingrid Eshun-Wilson
Affiliations
Meta-Analysis

Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people

Ajibola A Awotiwon et al. Cochrane Database Syst Rev. .

Abstract

Background: Cryptococcal disease remains one of the main causes of death in HIV-positive people who have low cluster of differentiation 4 (CD4) cell counts. Currently, the World Health Organization (WHO) recommends screening HIV-positive people with low CD4 counts for cryptococcal antigenaemia (CrAg), and treating those who are CrAg-positive. This Cochrane Review examined the effects of an approach where those with low CD4 counts received regular prophylactic antifungals, such as fluconazole.

Objectives: To assess the efficacy and safety of antifungal drugs for the primary prevention of cryptococcal disease in adults and children who are HIV-positive.

Search methods: We searched the CENTRAL, MEDLINE PubMed, Embase OVID, CINAHL EBSCOHost, WHO International Clinical Trials Registry Platform (WHO ICTRP), ClinicalTrials.gov, conference proceedings for the International AIDS Society (IAS) and Conference on Retroviruses and Opportunistic Infections (CROI), and reference lists of relevant articles up to 31 August 2017.

Selection criteria: Randomized controlled trials of adults and children, who are HIV-positive with low CD4 counts, without a current or prior diagnosis of cryptococcal disease that compared any antifungal drug taken as primary prophylaxis to placebo or standard care.

Data collection and analysis: Two review authors independently assessed eligibility and risk of bias, and extracted and analysed data. The primary outcome was all-cause mortality. We summarized all outcomes using risk ratios (RR) with 95% confidence intervals (CI). Where appropriate, we pooled data in meta-analyses. We assessed the certainty of the evidence using the GRADE approach.

Main results: Nine trials, enrolling 5426 participants, met the inclusion criteria of this review. Six trials administered fluconazole, while three trials administered itraconazole.Antifungal prophylaxis may make little or no difference to all-cause mortality (RR 1.07, 95% CI 0.80 to 1.43; 6 trials, 3220 participants; low-certainty evidence). For cryptococcal specific outcomes, prophylaxis probably reduces the risk of developing cryptococcal disease (RR 0.29, 95% CI 0.17 to 0.49; 7 trials, 5000 participants; moderate-certainty evidence), and probably reduces deaths due to cryptococcal disease (RR 0.29, 95% CI 0.11 to 0.72; 5 trials, 3813 participants; moderate-certainty evidence). Fluconazole prophylaxis may make no clear difference to the risk of developing clinically resistant Candida disease (RR 0.93, 95% CI 0.56 to 1.56; 3 trials, 1198 participants; low-certainty evidence); however, there may be an increased detection of fluconazole-resistant Candida isolates from surveillance cultures (RR 1.25, 95% CI 1.00 to 1.55; 3 trials, 539 participants; low-certainty evidence). Antifungal prophylaxis was generally well-tolerated with probably no clear difference in the risk of discontinuation of antifungal prophylaxis compared with placebo (RR 1.01, 95% CI 0.91 to 1.13; 4 trials, 2317 participants; moderate-certainty evidence). Antifungal prophylaxis may also make no difference to the risk of having any adverse event (RR 1.07, 95% CI 0.88 to 1.30; 4 trials, 2317 participants; low-certainty evidence), or a serious adverse event (RR 1.08, 95% CI 0.83 to 1.41; 4 trials, 888 participants; low-certainty evidence) when compared to placebo or standard care.

Authors' conclusions: Antifungal prophylaxis reduced the risk of developing and dying from cryptococcal disease. Therefore, where CrAG screening is not available, antifungal prophylaxis may be used in patients with low CD4 counts at diagnosis and who are at risk of developing cryptococcal disease.

PubMed Disclaimer

Conflict of interest statement

AA has no known conflicts of interest. SJ has no known conflicts of interest. GR has no known conflicts of interest. GM has no known conflicts of interest. IEW has no known conflicts of interest.

Figures

1
1
Study flow diagram.
2
2
‘Risk of bias' summary: review authors' judgements about each ‘Risk of bias' item for each included study
1.1
1.1. Analysis
Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 1 All‐cause mortality.
1.2
1.2. Analysis
Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 2 All‐cause mortality by CD4 count.
1.3
1.3. Analysis
Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 3 All‐cause mortality by baseline CrAG status.
1.4
1.4. Analysis
Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 4 All‐cause mortality by time‐to‐ART initiation.
1.5
1.5. Analysis
Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 5 All‐cause mortality by ART received.
1.6
1.6. Analysis
Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 6 All‐cause mortality by type of antifungal drug.
1.7
1.7. Analysis
Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 7 Cryptococcal disease occurrence.
1.8
1.8. Analysis
Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 8 Cryptococcal disease occurrence by CD4 count.
1.9
1.9. Analysis
Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 9 Cryptococcal disease occurrence by ART received.
1.10
1.10. Analysis
Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 10 Cryptococcal disease occurrence by type of antifungal drug.
1.11
1.11. Analysis
Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 11 Cryptococcal disease occurrence by time‐to‐ART initiation.
1.12
1.12. Analysis
Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 12 Cryptococcal disease occurrence by baseline CrAg status.
1.13
1.13. Analysis
Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 13 Cryptococcal‐specific mortality.
1.14
1.14. Analysis
Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 14 Clinical resistance of Candida to antifungal.
1.15
1.15. Analysis
Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 15 Microbiological resistance of Candida to fluconazole.
1.16
1.16. Analysis
Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 16 Treatment discontinuation.
1.17
1.17. Analysis
Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 17 Any serious adverse event.
1.18
1.18. Analysis
Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 18 Any adverse events.
1.19
1.19. Analysis
Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 19 Common adverse events.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Chariyalertsak 2002 {published data only}
    1. Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clinical Infectious Diseases 2002;34(2):277‐84. [PUBMED: 11740718] - PubMed
Chetchotisakd 2004 {published data only}
    1. Chetchotisakd P, Sungkanuparph S, Thinkhamrop B, Mootsikapun P, Boonyaprawit P. A multicentre, randomized, double‐blind, placebo‐controlled trial of primary cryptococcal meningitis prophylaxis in HIV‐infected patients with severe immune deficiency. HIV Medicine 2004;5(3):140‐3. [PUBMED: 15139978] - PubMed
Goldman 2005 {published data only}
    1. Goldman M, Cloud GA, Wade KD, Reboli AC, Fichtenbaum CJ, Hafner R, et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clinical Infectious Diseases 2005;41(10):1473‐80. - PubMed
    1. NCT00000951. A study to compare the use of fluconazole as continuous therapy versus periodic therapy in HIV‐positive patients with recurrent thrush [A Phase IV randomized study of the use of fluconazole as chronic suppressive therapy versus episodic therapy in HIV positive subjects with recurrent oropharyngeal candidiasis]. clinicaltrials.gov/ct2/show/NCT00000951 (first posted 31 August 2001).
Hakim 2017 {published data only}
    1. Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C, et al. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa. New England Journal of Medicine 2017;377(3):233‐45. - PMC - PubMed
    1. ISRCTN43622374. Reduction of early mortality in HIV‐infected African adults and children starting antiretroviral therapy [Reduction of Early mortALITY in HIV‐infected African adults and children starting antiretroviral therapy: a randomised controlled trial]. isrctn.com/ISRCTN43622374 (first received 28 September 2011).
McKinsey 1999 {published data only}
    1. Goldman M, Cloud GA, Smedema M, LeMonte A, Connolly P, McKinsey DS, et al. Does long‐term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? The National Institute of Allergy and Infectious Diseases Mycoses study group. Antimicrobial Agents and Chemotherapy 2000;44(6):1585‐7. [PUBMED: 10817713] - PMC - PubMed
    1. Monte AM, Goldman M, Smedema ML, Connolly PA, McKinsey DS, Cloud GA, et al. DNA fingerprinting of serial Candida albicans isolates obtained during itraconazole prophylaxis in patients with AIDS. Medical Mycology 2001;39(2):207‐13. [PUBMED: 11346270] - PubMed
    1. McKinsey DS, Wheat LJ, Cloud GA, Pierce M, Black JR, Bamberger DM, et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo‐controlled, double‐blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clinical Infectious Diseases 1999;28(5):1049‐56. [PUBMED: 10452633] - PubMed
Parkes‐Ratanshi 2011 {published data only}
    1. ISRCTN76481529. Primary prevention of invasive cryptococcal disease using fluconazole prophylaxis in Human Immunodeficiency Virus (HIV) infected Ugandans. isrctn.com/ISRCTN76481529 (first received 18 May 2001).
    1. Parkes‐Ratanshi R, Wakeham K, Kamali A, Levin J, Coutinho A, Whitworth J, et al. Successful primary prevention of cryptococcal disease using fluconazole prophylaxis in HIV‐infected Ugandan adults (cryptopro): o26. HIV Medicine 2009;10:8‐9.
    1. Parkes‐Ratanshi R, Wakeham K, Levin J, Namusoke D, Whitworth J, Coutinho A, et al. Primary prophylaxis of cryptococcal disease with fluconazole in HIV‐positive Ugandan adults: a double‐blind, randomised, placebo‐controlled trial. Lancet Infectious Diseases 2011;11(12):933‐41. [PUBMED: 21982529] - PMC - PubMed
Revankar 1998 {published data only}
    1. Revankar SG, Kirkpatrick WR, McAtee RK, Dib OP, Fothergill AW, Redding SW, et al. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV‐infected patients: clinical outcomes and development of fluconazole resistance. American Journal of Medicine 1998;1:7‐11. - PubMed
Schuman 1997 {published data only}
    1. Schuman P, Capps L, Peng G, Vazquez J, el‐Sadr W, Goldman AI, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double‐blind, placebo‐controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Annals of Internal Medicine 1997;126(9):689‐96. - PubMed
    1. Vazquez JA, Peng G, Sobel JD, Steele‐Moore L, Schuman P, Holloway W, et al. Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus‐infected women receiving fluconazole prophylaxis. Clinical Infectious Diseases 2001;33(7):1069‐75. - PubMed
    1. Vazquez JA, Sobel JD, Peng G, Steele‐Moore L, Schuman P, Holloway W, et al. Evolution of vaginal Candida species recovered from human immunodeficiency virus‐infected women receiving fluconazole prophylaxis: the emergence of Candida glabrata? Terry Beirn Community Programs for Clinical Research in AIDS (CPCRA). Clinical Infectious Diseases 1999;28(5):1025‐31. - PubMed
Smith 2001 {published data only}
    1. Smith DE, Bell J, Johnson M, Youle M, Gazzard B, Tchamouroff S, et al. A randomized, double‐blind, placebo‐controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection. HIV Medicine 2001;2(2):78‐83. [PUBMED: 11737382] - PubMed

References to studies excluded from this review

Anonymous 1995 {published data only}
    1. Anonymous. Fluconazole may have edge in preventing infections. AIDS Alert 1995;10(5):67‐8.
Anonymous 2001 {published data only}
    1. Anonymous. Antifungal drug fluconazole found to be effective in preventing thrush in people who are HIV positive. AHRQ Research Activities 2001;250:15.
Apisarnthanarak 2008a {published data only}
    1. Apisarnthanarak A, Mundy LM. The impact of primary prophylaxis for cryptococcosis on fluconazole resistance in Candida species. Journal of Acquired Immune Deficiency Syndromes 2008;47(5):644‐5. - PubMed
Chaiwarith 2011 {published data only}
    1. Chaiwarith R, Fakthongyoo A, Praparattanapan J, Boonmee D, Sirisanthana T, Supparatpinyo K. Itraconazole vs fluconazole as a primary prophylaxis for fungal infections in HIV‐infected patients in Thailand. Curr HIV Research 2011;9(5):334‐8. - PubMed
Chaiwarith 2013 {published data only}
    1. Chaiwarith R, Praparattanapan J, Nuntachit N, Kotarathitithum W, Supparatpinyo K. Discontinuation of primary and secondary prophylaxis for opportunistic infections in HIV‐infected patients who had CD4+ cell count 3 but undetectable plasma HIV‐1 RNA: an open‐label randomized controlled trial. AIDS Patient Care and STDs 2013;27(2):71‐6. - PubMed
Geletko 1996 {published data only}
    1. Geletko SM, Segarra M, Mayer KH, Fiore TC, Bettencourt FA, Flanigan TP, et al. Electronic compliance assessment of antifungal prophylaxis for human immunodeficiency virus‐infected women. Antimicrobial Agents and Chemotherapy 1996;40(6):1338‐41. - PMC - PubMed
Havlir 1998 {published data only}
    1. Havlir DV, Dube MP, McCutchan JA, Forthal DN, Kemper CA, Dunne MW, et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clinical Infectious Diseases 1998;27(6):1369‐75. - PubMed
Jüst‐Nubling 1991 {published data only}
    1. Jüst‐Nubling G, Gentschew G, Meissner K, Odewald J, Staszewski S, Helm EB, et al. Fluconazole prophylaxis of recurrent oral candidiasis in HIV‐positive patients. European Journal of Clinical Microbiology & Infectious Diseases 1991;10(11):917‐21. - PubMed
Manfredi 1997 {published data only}
    1. Manfredi R, Mastroianni A, Coronado OV, Chiodo F. Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection. Archives of Internal Medicine 1997;157(1):64‐9. - PubMed
Manosuthi 2005 {published data only}
    1. Manosuthi W, Chumpathat N, Chaovavanich A, Sungkanuparph S. Safety and tolerability of nevirapine‐based antiretroviral therapy in HIV‐infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study. BMC Infect Diseases 2005;5:67. - PMC - PubMed
Manosuthi 2006 {published data only}
    1. Manosuthi W, Sungkanuparph S, Thongyen S, Chumpathat N, Eampokalap B, Thawornwan U, et al. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV‐infected patients with/without fluconazole prophylaxis. Journal of the Medical Association of Thailand 2006;89(6):795‐802. - PubMed
Mfinanga 2015 {published data only}
    1. Mfinanga S, Chanda D, Kivuyo SL, Guinness L, Bottomley C, Simms V, et al. Cryptococcal meningitis screening and community‐based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open‐label, randomised controlled trial. Lancet 2015;385(9983):2173‐82. - PubMed
Micol 2010 {published data only}
    1. Micol R, Tajahmady A, Lortholary O, Balkan S, Quillet C, Dousset JP, et al. Cost‐effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia. PLoS One 2010;5(11):e13856. - PMC - PubMed
Mylonakis 1998 {published data only}
    1. Mylonakis E, Flanigan TP. Editorial response: Antifungal prophylaxis with weekly fluconazole for patients with AIDS. Clinical Infectious Diseases 1998;27(6):1376‐8. - PubMed
Penzak 1998 {published data only}
    1. Penzak SR, Gubbins PO. Preventing and treating azole‐resistant oropharyngeal candidiasis in HIV‐infected patients. American Journal of Health‐System Pharmacy 1998;55(3):279‐83. - PubMed
Powderly 1995 {published data only}
    1. Powderly WG, Finkelstein D, Feinberg J, Frame P, He W, Horst C, et al. A randomised trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. New England Journal of Medicine 1995;332(11):700‐5. - PubMed
Singh 1996 {published data only}
    1. Singh N, Barnish MJ, Berman S, Bender B, Wagener MM, Rinaldi MG, et al. Low‐dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of ≤ 100/mm³: demonstration of efficacy in a positive, multicenter trial. Clinical Infectious Diseases 1996;23(6):1282‐6. - PubMed
Stevens 1991 {published data only}
    1. Stevens DA, Greene SI, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome‐related complex. Randomized, double‐blind, placebo‐controlled study of 100‐mg oral fluconazole daily. Archives of Internal Medicine 1991;151(12):2458‐64. [PUBMED: 1747004] - PubMed
Svoboda 1995 {published data only}
    1. Svoboda J. Prophylaxis of opportunistic infections in HIV infection. Journal of Community Health 1995;20(2):203‐7. - PubMed
Thurey 2008 {published data only}
    1. Thurey J, Molyneux E. Evidence behind the WHO guidelines: Hospital Care for Children: the usefulness of azole prophylaxis against cryptococcal meningitis in HIV‐positive children. Journal of Tropical Pediatrics 2008;54(6):361‐3. - PubMed
Wakeham 2010 {published data only}
    1. Wakeham K, Parkes‐Ratanshi R, Watson V, Ggayi AB, Khoo S, Lalloo DG. Co‐administration of fluconazole increases nevirapine concentrations in HIV‐infected Ugandans. Journal of Antimicrobial Chemotherapy 2010;65(2):316‐9. - PMC - PubMed
White 1993 {published data only}
    1. White MH. Antifungal prophylaxis. Current Opinion in Infectious Diseases 1993;6(6):737‐839.

References to studies awaiting assessment

Anonymous 1998 {published data only}
    1. Anonymous. Preventing mucosal candidiasis in HIV‐infected women. Emergency Medicine 1998;30(2):112‐5.
Smith 1999 {published data only}
    1. Smith D, Midgley J, Gazzard B. A randomised, double‐blind study of itraconazole versus placebo in the treatment and prevention of oral or oesophageal candidosis in patients with HIV infection. International Journal of Clinical Practice 1999;53(5):349‐52. [PUBMED: 10695098] - PubMed

Additional references

Apisarnthanarak 2008b
    1. Apisarnthanarak A, Jirayasethpong T, Sa‐nguansilp C, Thongprapai H, Kittihanukul C, Kamudamas A, et al. Antiretroviral drug resistance among antiretroviral‐naive persons with recent HIV infection in Thailand. HIV Medicine 2008;9(5):322‐5. [PUBMED: 18400079] - PubMed
Brion 2007
    1. Brion LP, Uko SE, Goldman DL. Risk of resistance associated with fluconazole prophylaxis: systematic review. Journal of Infection 2007;54(6):521‐9. [PUBMED: 17239952] - PubMed
CDC 2017
    1. Panel on Opportunistic Infections in HIV‐Infected Adults, Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV‐infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (accessed 3 Sept 2017).
Cheong 2013
    1. Cheong JW, McCormack J. Fluconazole resistance in cryptococcal disease: emerging or intrinsic?. Medical Mycology 2013;51(3):261‐9. [PUBMED: 22989195] - PubMed
DAIDS 2014
    1. DAIDS Grading Table Working Group. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. Version 2.0. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services. November 2014. Available from rsc.tech‐res.com/docs/default‐source/safety/daids_ae_grading_table_v2_nov2014.pdf.
GRADEpro GDT [Computer program]
    1. McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 6 August 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Higgins 2011
    1. Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
HIV drug interactions 2018
    1. Liverpool HIV drug interactions. HIV drug interaction checker. www.hiv‐druginteractions.org/checker (accessed 22 May 2018).
Jarvis 2010
    1. Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T, Harrison TS. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infectious Diseases 2010;10:67. [PUBMED: 20230635] - PMC - PubMed
Kambugu 2008
    1. Kambugu A, Meya DB, Rhein J, O'Brien M, Janoff EN, Ronald AR, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clinical Infectious Diseases 2008;46(11):1694‐701. [PUBMED: 18433339] - PMC - PubMed
Kontoyiannis 2002
    1. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 2002;359(9312):1135‐44. [PUBMED: 11943280] - PubMed
Lessells 2011
    1. Lessells RJ, Mutevedzi PC, Heller T, Newell ML. Poor long‐term outcomes for cryptococcal meningitis in rural South Africa. South African Medical Journal 2011;101(4):251‐2. [PUBMED: 21786729] - PubMed
McLachlan 1996
    1. McLachlan AJ, Tett SE. Pharmacokinetics of fluconazole in people with HIV infection: a population analysis. British Journal of Clinical Pharmacology 1996;41(4):291‐8. [PUBMED: 8730974] - PMC - PubMed
Mirza 2003
    1. Mirza SA, Phelan M, Rimland D, Graviss E, Hamill R, Brandt ME, et al. The changing epidemiology of cryptococcosis: an update from population‐based active surveillance in 2 large metropolitan areas, 1992‐2000. Clinical Infectious Diseases 2003;36(6):789‐94. [PUBMED: 12627365] - PubMed
Pierard 2000
    1. Pierard GE, Arrese JE, Pierard‐Franchimont C. Itraconazole. Expert Opinion on Pharmacotherapy 2000;1(2):287‐304. - PubMed
Pound 2011
    1. Pound MW, Townsend ML, Dimondi V, Wilson D, Drew RH. Overview of treatment options for invasive fungal infections. Medical Mycology 2011;49(6):561‐80. [PUBMED: 21366509] - PubMed
Rajasingham 2017
    1. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV‐associated cryptococcal meningitis: an updated analysis. Lancet Infectious Diseases 2017;17(8):873‐81. [PUBMED: 28483415] - PMC - PubMed
RevMan 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rhein 2016
    1. Rhein J, Morawski BM, Hullsiek K, Nabeta H, Kiggundu R, Tugume L, et al. Efficacy of adjunctive sertraline for the treatment of HIV‐associated cryptococcal meningitis: an open‐label dose‐ranging study. Lancet Infectious Diseases 2016;16(7):809‐18. - PMC - PubMed
Skolnik 2017
    1. Skolnik K, Huston S, Mody CH. Cryptococcal lung infections. Clinical Chest Medicine 2017;38:451‐64. - PubMed
Ssekitoleko 2013
    1. Ssekitoleko R, Kamya MR, Reingold AL. Primary prophylaxis for cryptococcal meningitis and impact on mortality in HIV: a systematic review and meta‐analysis. Future Virology 2013;8(9):917‐30. [PUBMED: 24368930] - PMC - PubMed
Tenforde 2017
    1. Tenforde MW, Mokomane M, Leeme T, Patel RKK, Lekwape N, Ramodimoosi C, et al. Advanced HIV disease in Botswana following successful antiretroviral therapy rollout: incidence of and temporal trends in cryptococcal meningitis. Clinical Infectious Diseases 2017;65(5):779‐86. [PUBMED: 28505328] - PMC - PubMed
Wall 2014
    1. Wall EC, Everett DB, Mukaka M, Bar‐Zeev N, Feasey N, Jahn A, et al. Bacterial meningitis in Malawian adults, adolescents, and children during the era of antiretroviral scale‐up and Haemophilus influenzae type B vaccination, 2000‐2012. Clinical Infectious Diseases 2014;58(10):e137‐45. - PMC - PubMed
WHO 2011
    1. World Health Organization. Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV‐infected adults, adolescents and children: World Health Organization. December 2011. Available from apps.who.int/iris/bitstream/handle/10665/44786/9789241502979_eng.pdf?seq.... - PubMed
WHO 2016
    1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd edition. World Health Organization. 2016. Available from apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.pdf?se....
Williamson 2017
    1. Williamson PR, Jarvis JN, Panackal AA, Fisher MC, Molloy SF, Loyse A, et al. Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. Nature Reviews. Neurology 2017;13(1):13‐24. [PUBMED: 27886201] - PubMed

References to other published versions of this review

Chang 2004
    1. Chang LW, Phipps WT, Rutherford GW. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD004773] - DOI - PubMed
Chang 2005
    1. Chang LW, Phipps WT, Kennedy GE, Rutherford GW. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD004773.pub2] - DOI - PubMed

Publication types

MeSH terms